GLP-1 Pill vs Injection: Oral vs Injectable Semaglutide

Quick answer: Wegovy’s pill and Wegovy’s injection are the same drug — semaglutide — delivered two different ways. The injection is a once-weekly shot approved June 4, 2021; the pill is oral semaglutide 25 mg taken once daily, approved Dec 22, 2025. In the FDA label’s own trials the two finish close: a 13.6% mean weight reduction at week 64 for the tablet (Study 7) against 14.9% at week 68 for the injection (Study 2), both intent-to-treat versus 2.4% on placebo. The pill removes the needle and the cold chain but adds a strict morning routine.

Oral vs injectable semaglutide, side by side

Same molecule, different delivery. Almost every practical difference between the two forms follows from that table.

Dosing, storage and trial figures are read from the FDA-approved Wegovy labeling, which covers both forms; the price row is from our 2026 GLP-1 pricing guide.

Approval and indication status: two decisions, four years apart

The injectable reached the market first. NDA 215256 was approved on June 4, 2021 (Drugs@FDA, NDA 215256), and it now carries three indications: weight reduction in adults and in pediatric patients aged 12 and older with obesity; reduction of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight; and treatment of noncirrhotic MASH with moderate to advanced liver fibrosis under accelerated approval (FDA labeling).

The tablet followed on Dec 22, 2025 under NDA 218316 — the first oral GLP-1 approved for weight management (Drugs@FDA, NDA 218316). Its indications overlap but are narrower: weight reduction in adults with obesity, or with overweight plus at least one weight-related condition, and the same cardiovascular risk-reduction claim. It carries no pediatric obesity indication and no MASH indication. Those are differences in the label, not in the molecule. Neither form carries a psychiatric indication either: GLP-1s in psychiatric indications remain unapproved, with Phase 3 work in alcohol use disorder still recruiting and the depression program designed but not yet read out.

Administration: a weekly needle vs a daily 30-minute rule

The injection goes in subcutaneously once weekly, on the same day each week, at any time of day, with or without food (FDA labeling).

The pill has to be taken inside a narrow window: once daily in the morning on an empty stomach, with water only — no more than 4 ounces — and nothing else for at least 30 minutes afterwards, other oral medicines included. The constraint is absorption. Oral semaglutide is taken up mainly in the stomach, and the label reports higher blood levels when the tablet was swallowed with 50 mL of water than with 240 mL. A bigger glass of water, or a sip of coffee, changes how much of the dose gets through.

The label also writes both switching directions in. A patient on the 2.4 mg injection can move to 25 mg tablets one week after the last injection; a patient on the tablets can move to the injection the day after the last tablet.

Refrigeration: the pill travels, the pen does not

The single-dose pen is stored in the refrigerator at 2 to 8 °C (36 to 46 °F), and can be kept at 8 to 30 °C (46 to 86 °F) for up to 28 days before the cap is removed (FDA labeling). Tablets are stored at 20 to 25 °C (68 to 77 °F) in the original bottle, in a dry place, with no refrigeration requirement. For anyone who travels, works away from a fridge, or has had a cold-chain shipment arrive warm, that is the practical difference between the two forms.

Price: the pill is the cheaper cash-pay entry point

List prices for brand-name semaglutide run roughly $1,028 to $1,349 a month, but few patients pay list. Manufacturer cash-pay programs put the Wegovy pill at about $149 to $199 a month, and injectable Wegovy from about $199 on introductory pricing that rises to $349 (GLP-1 Daily, our 2026 GLP-1 pricing guide). With insurance plus a manufacturer savings card, either form can fall to $25 or less. On Medicare, the GLP-1 Bridge demonstration covers Wegovy as an injection or a tablet for about $50 a month through Dec 31, 2027 (CMS).

Compounded semaglutide has been the budget tier at roughly $99 to $397 a month, in whatever form a pharmacy could legally supply. The Fifth Circuit’s Aug 27, 2026 ruling against the FDA’s compounding appeals narrows that: mass compounding of essentially copies is no longer permitted, and the surviving path is a patient-specific formulation with a documented clinical difference. Both the pill and the injection sit inside that change — see our compounded GLP-1 ruling explainer.

Which form patients are actually choosing

Prescription counts are the closest thing to a scoreboard, and they now run in the pill’s favour on growth. In the Sept 11, 2026 edition of Fierce Pharma’s Oral GLP-1 Tracker — built on IQVIA prescription data cited by Citi — the Wegovy pill recorded roughly 183,000 weekly prescriptions, against roughly 47,500 for Foundayo (orforglipron) in the same reported week. Both were the highest weekly totals either product had recorded.

That series measures the pill, not the split. The tracker publishes totals by product and not an oral-versus-injectable breakdown inside the class, so the 183,000 figure from the Sept 11, 2026 edition cannot by itself say whether the pill is expanding GLP-1 use or replacing shots; the class-level read from the same edition points to expansion. Our oral GLP-1 comparison carries the dated market-data table, and our weekly prescription breakdown follows the trend edition by edition.

Frequently asked questions

Is the GLP-1 pill as effective as the injection?

They land close in the label trials. Intent-to-treat, oral semaglutide 25 mg produced a 13.6% mean weight reduction at week 64 and the 2.4 mg injection 14.9% at week 68, each against 2.4% on placebo. Those are separate studies rather than a head-to-head trial, so treat the gap as approximate.

Do you have to refrigerate the GLP-1 pill?

No. Wegovy tablets are stored at 20 to 25 °C (68 to 77 °F) in the original bottle, in a dry place. The injection is different: the pen stays refrigerated at 2 to 8 °C (36 to 46 °F) and can sit at 8 to 30 °C for no more than 28 days before the cap comes off.

Can you switch between the pill and the injection?

Yes. The label describes both directions: moving from the 2.4 mg injection to 25 mg tablets starts one week after the last injection, and moving from tablets to the injection starts the day after the last tablet.

Why must oral semaglutide be taken on an empty stomach?

Because absorption happens mainly in the stomach. The label requires an empty stomach, water only (up to 4 ounces) and a 30-minute wait before food, drink or other oral medicines; swallowing the tablet with a larger volume of water lowered blood levels in the label’s data.

Is the pill cheaper than the injection?

For cash-paying patients, usually yes. Manufacturer cash-pay pricing puts the Wegovy pill at roughly $149 to $199 a month and injectable Wegovy from about $199 a month on introductory pricing. With insurance plus a savings card, either form can fall to $25 or less.

Bottom line

If the needle is the obstacle, the pill puts the same molecule within reach — at the cost of a daily empty-stomach routine and a 30-minute wait, and without the injection’s pediatric and MASH indications. If the morning routine is the obstacle, the weekly injection avoids it. Either way, the choice belongs with a prescriber, not a price page.

PeptidesBeat is an independent editorial publication covering peptide research, policy, and industry developments. We do not sell peptides, recommend dosing, or provide medical advice. All content is informational. This page does not recommend or link to any pharmacy, telehealth provider or seller; consult a licensed healthcare provider for any medical question.